FDA approves first biosimilar to treat macular degeneration
The Food and Drug Administration Friday the first biosimilar to treat neovascular age-related macular degeneration, a leading cause of vision loss and blindness for seniors. The biosimilar (Byooviz) also was approved to treat fluid build-up following vein blockage in the retina and myopic choroidal neovascularization, a vision-threatening complication of nearsightedness.
鈥淐ontinuing to grow the number of biosimilar approvals is a key part of our efforts to provide greater access to treatment options for patients, increase competition and potentially lower costs,鈥 said Sarah Yim, M.D., who directs the Office of Therapeutic Biologics and Biosimilars in FDA鈥檚 Center for Drug Evaluation and Research.
Related News Articles
Headline
The White House Feb. 1 announced it placed tariffs on imported goods from Canada, Mexico and China. The tariffs for Mexico and Canada have since been delayed鈥
Headline
The Food and Drug Administration is evaluating Chinese-made plastic syringes used to inject or withdraw fluids from the body, citing concern that they may鈥
Headline
Draeger Medical, Inc. is recalling its Carina Ventilators due to the presence of contaminants in the device鈥檚 airpath, which exceed acceptable levels if鈥
Headline
Crews are working to restore power and assess damage to a Pfizer plant in North Carolina that makes sterile injectables for U.S. hospitals after a tornado鈥
Headline
Federal agencies last month stopped over 500 unapproved pharmaceutical products and medical devices, including opioid and other controlled substances, from鈥
Headline
The Consumer Financial Protection Bureau, Centers for Medicare & Medicaid Services, Department of Health and Human Services, and Department of the Treasury鈥